MFC Co

MFC Co Forward P/E

The Forward P/E Ratio of MFC Co (432980.KQ) as of Nov 3, 2026 is -23.91. In the previous year, Forward P/E Ratio was -39.18 — a change of -38.97% (higher).

Forward P/E

-23.91

YoY

-38.97%

Last updated:

Forward P/E Ratio of MFC Co is 2024 -23.91 . Forward P/E Ratio of MFC Co was 2023 -39.18 . It decreases by -38.97% higher compared to the previous year.

The MFC Co Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2022
93.93 KRW
Jan 1, 2023
-39.18 KRW
Jan 1, 2024
-23.91 KRW
The MFC Co Forward P/E history
YEARForward P/EYoY
-23.91-38.97%
-39.18-141.71%
93.93—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

Forward P/E Ratio of MFC Co is -23.91 in 2024.

Forward P/E Ratio of MFC Co changed from -39.18 to -23.91, representing a -38.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio MFC Co since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's MFC Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MFC Co

All Key Metrics — MFC Co